BCTXW
Income statement / Annual
Last year (2025), BriaCell Therapeutics Corp.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, BriaCell Therapeutics Corp.'s net income was -$26.49 M.
See BriaCell Therapeutics Corp.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
07/31/2025 |
07/31/2024 |
07/31/2023 |
07/31/2022 |
07/31/2021 |
07/31/2020 |
07/31/2019 |
07/31/2018 |
07/31/2017 |
07/31/2016 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$107.34 K
|
$82.58 K
|
$20.49 K
|
$19.39 K
|
$19.44 K
|
$18.74 K
|
$18.74 K
|
$16.89 K
|
$290.00
|
$1.79 K
|
| Gross Profit |
-$107.34 K
|
-$82.58 K
|
-$20.49 K
|
-$19.39 K
|
-$19.44 K
|
-$18.74 K
|
-$18.74 K
|
-$16.89 K
|
-$290.00
|
-$1.79 K
|
| Gross Profit Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$21.27 M
|
$26.75 M
|
$15.34 M
|
$8.02 M
|
$1.32 M
|
$2.22 M
|
$3.74 M
|
$2.39 M
|
$1.71 M
|
$723.43 K
|
| General & Administrative Expenses |
$5.93 M
|
$0.00
|
$7.94 M
|
$7.27 M
|
$4.96 M
|
-$1.37 M
|
-$932.00 K
|
-$1.05 M
|
$876.16 K
|
$942.02 K
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$5.93 M
|
$5.97 M
|
$7.94 M
|
$7.27 M
|
-$3.68 M
|
-$1.37 M
|
-$932.00 K
|
-$1.05 M
|
$876.16 K
|
$942.02 K
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
-$15.29 M
|
-$1.33 M
|
-$64.39 K
|
-$3.75 M
|
-$313.00 K
|
$232.68
|
$1.37 K
|
| Operating Expenses |
$27.20 M
|
$32.73 M
|
$23.27 M
|
-$3.39 K
|
$6.97 M
|
$3.92 M
|
-$946.00 K
|
$5.41 M
|
$2.58 M
|
$1.67 M
|
| Cost And Expenses |
$27.39 M
|
$32.81 M
|
$23.27 M
|
$15.29 M
|
$6.97 M
|
$3.92 M
|
-$946.00 K
|
$5.41 M
|
$2.58 M
|
$1.67 M
|
| Interest Income |
$120.76 K
|
$283.51 K
|
$891.21 K
|
$136.73 K
|
$3.15 K
|
$39.48
|
$9.13 K
|
$12.27 K
|
$5.16 K
|
$3.63 K
|
| Interest Expense |
$37.23 K
|
$0.00
|
$0.00
|
$979.00
|
$46.10 K
|
$29.48 K
|
$23.82 K
|
$15.63 K
|
$5.16 K
|
$3.63 K
|
| Depreciation & Amortization |
$107.34 K
|
$82.58 K
|
$15.27 K
|
$19.39 K
|
$19.44 K
|
$18.74 K
|
$18.74 K
|
$16.89 K
|
$290.00
|
$1.79 K
|
| EBITDA |
-$26.59 M |
-$4.77 M |
-$27.22 M |
-$34.05 M |
-$6.95 M |
-$3.97 M |
-$5.74 M |
-$5.38 M |
-$3.22 M |
-$2.21 M |
| EBITDA Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$652.99 K
|
$27.95 M
|
$2.97 M
|
-$11.69 M
|
-$6.77 M
|
-$78.90 K
|
$905.30 K
|
-$436.00 K
|
-$2.49 K
|
-$37.59 K
|
| Income Before Tax |
-$26.73 M
|
-$4.85 M
|
-$26.77 M
|
-$34.37 M
|
-$13.82 M
|
-$5.39 M
|
-$6.23 M
|
-$5.41 M
|
-$3.22 M
|
-$2.21 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
-$153.00 K
|
$30.73 K
|
$6.58 M
|
-$72.25 K
|
$343.74 K
|
-$319.00 K
|
$1.99 K
|
$29.24 K
|
| Net Income |
-$26.49 M
|
-$4.72 M
|
-$20.30 M
|
-$11.58 M
|
-$2.90 M
|
$1.39 M
|
$602.68 K
|
$1.07 M
|
-$2.58 M
|
-$1.70 M
|
| Net Income Ratio |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
| EPS |
-62.6 |
-42.99 |
-1.74 |
-1.73 |
-0.19 |
-5.64 |
1.04 |
2.49 |
-7.61 |
-5.88 |
| EPS Diluted |
-62.6 |
-42.99 |
-1.74 |
-1.73 |
-0.19 |
-5.64 |
1.04 |
2.49 |
-7.32 |
-5.88 |
| Weighted Average Shares Out |
$423.11 K
|
$109.70 K
|
$15.62 M
|
$15.49 M
|
$15.27 M
|
$713.89 K
|
$579.66 K
|
$427.81 K
|
$339.71 K
|
$288.44 K
|
| Weighted Average Shares Out Diluted |
$423.11 K
|
$109.70 K
|
$15.62 M
|
$15.52 M
|
$15.27 M
|
$713.89 K
|
$579.66 K
|
$427.82 K
|
$352.98 K
|
$288.44 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
